{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:26:50Z","timestamp":1793824010831,"version":"4.6.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The Bill & Melinda Gates Foundation Major Project: Malaria R&D sourcing & facilitation in China","award":["INV-061480"],"award-info":[{"award-number":["INV-061480"]}]},{"DOI":"10.13039\/501100001809","name":"The Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82074301"],"award-info":[{"award-number":["82074301"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"The Science and the Technology Project of Guangzhou","award":["202206010066"],"award-info":[{"award-number":["202206010066"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Parasites Vectors"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The aim of this study was to explore the effect of mass drug administration (MDA) on malaria transmission in low-endemic malaria areas.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Mass drug administration of artemisinin-piperaquine (AP) + primaquine (PMQ) was targeted to 17,438 individuals in the Agua Grande region of S\u00e3o Tom\u00e9 and Pr\u00edncipe (STP). The participants were allocated to either a three-round MDA (3-MDA) group or to a two-round MDA (2-MDA) group. The coverage rate, compliance, adverse events and other indicators were evaluated.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Mass drug administration coverage rate in the 3-MDA group (20,548 person-times) was 84.23\u201389.14%, with a compliance of 68.38%. MDA coverage rate in the 2-MDA group (15,365 person-times) was 87.30\u201393.23%, with a compliance of 80.70%. The rates of MDA-related adverse reactions were low in both the 3-MDA (0.75%) and 2-MDA (0.72%) groups, and no serious adverse reactions were observed. Malaria incidence decreased by 80.47% (<jats:italic>z<\/jats:italic>\u2009=\u2009\u2212\u00a02.35, <jats:italic>P<\/jats:italic>\u2009=\u20090.019) and 72.27% (<jats:italic>z<\/jats:italic>\u2009=\u2009\u2212\u00a00.89, <jats:italic>P<\/jats:italic>\u2009=\u20090.372) in the 3-MDA and 2-MDA groups, respectively, within 1 year.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Two or three rounds of MDA with AP and PMQ in STP safely and rapidly reduced the prevalence of malaria cases and infections. It is possible that two rounds of MDA in certain districts may achieve the desired outcomes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Graphical Abstract<\/jats:title>\n          <\/jats:sec>","DOI":"10.1186\/s13071-025-06768-1","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T13:58:50Z","timestamp":1747403930000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A non-randomized, open-label study to assess the impact of rounds of mass drug administration with artemisinin-piperaquine plus primaquine on malaria in S\u00e3o Tom\u00e9 Island"],"prefix":"10.1186","volume":"18","author":[{"given":"Mingqiang","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruixiang","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herodes Sacramento","family":"Rampao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Alberto Bandeira","family":"D\u2019almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guozhuang","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changsheng","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenfeng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,16]]},"reference":[{"key":"6768_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph192214817","author":"Y Wang","year":"2022","unstructured":"Wang Y, Li M, Guo W, Deng C, Zou G, Song J. Burden of malaria in Sao Tome and principe, 1990\u20132019: findings from the Global Burden of Disease study 2019. Int J Environ Res Public Health. 2022;19(22):14817. https:\/\/doi.org\/10.3390\/ijerph192214817.","journal-title":"Int J Environ Res Public Health"},{"key":"6768_CR2","volume-title":"World malaria report 2023","author":"WHO","year":"2023","unstructured":"WHO. World malaria report 2023. Geneva: WHO; 2023."},{"key":"6768_CR3","volume-title":"Mass drug administration for falciparum malaria: a practical field manual","author":"WHO","year":"2017","unstructured":"WHO. Mass drug administration for falciparum malaria: a practical field manual. Geneva: WHO; 2017."},{"key":"6768_CR4","doi-asserted-by":"publisher","first-page":"CD008846","DOI":"10.1002\/14651858.CD008846.pub3","volume":"9","author":"MP Shah","year":"2021","unstructured":"Shah MP, Hwang J, Choi L, Lindblade KA, Kachur SP, Desai M. Mass drug administration for malaria. Cochrane Database Syst Rev. 2021;9:CD008846. https:\/\/doi.org\/10.1002\/14651858.CD008846.pub3.","journal-title":"Cochrane Database Syst Rev"},{"key":"6768_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4269\/ajtmh.20-0729","volume":"103","author":"PL Alonso","year":"2020","unstructured":"Alonso PL. The role of mass drug administration of antimalarials. Am J Trop Med Hyg. 2020;103:1\u20132. https:\/\/doi.org\/10.4269\/ajtmh.20-0729.","journal-title":"Am J Trop Med Hyg"},{"key":"6768_CR6","doi-asserted-by":"publisher","unstructured":"Agaba BB, Rugera SP, Mpirirwe R, Atekat M, Okubal S, Masereka K, et al. Asymptomatic malaria infection, associated factors and accuracy of diagnostic tests in a historically high transmission setting in Northern Uganda. Malar J. 2022;21:392. https:\/\/doi.org\/10.1186\/s12936-022-04421-1.","DOI":"10.1186\/s12936-022-04421-1"},{"key":"6768_CR7","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1586\/eri.13.45","volume":"11","author":"A Kim","year":"2013","unstructured":"Kim A, Lindblade LS, Aaron S, Patrick Kachur S, Laurence S. The silent threat asymptomatic parasitemia and malaria transmission. Expert Rev Anti Infect Ther. 2013;11:623\u201339. https:\/\/doi.org\/10.1586\/eri.13.45.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"6768_CR8","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1016\/j.jiph.2021.08.032","volume":"14","author":"A Singh","year":"2021","unstructured":"Singh A, Bhandari S, Das A, Bharti PK. Asymptomatic low-density Plasmodium falciparum infections: a challenge in malaria elimination in India. J Infect Public Health. 2021;14:1600\u20132. https:\/\/doi.org\/10.1016\/j.jiph.2021.08.032.","journal-title":"J Infect Public Health"},{"key":"6768_CR9","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.pt.2015.11.015","volume":"32","author":"B Galatas","year":"2016","unstructured":"Galatas B, Bassat Q, Mayor A. Malaria parasites in the asymptomatic: looking for the hay in the haystack. Trends Parasitol. 2016;32:296\u2013308. https:\/\/doi.org\/10.1016\/j.pt.2015.11.015.","journal-title":"Trends Parasitol"},{"key":"6768_CR10","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1080\/14787210.2019.1693259","volume":"17","author":"J Cheaveau","year":"2019","unstructured":"Cheaveau J, Mogollon DC, Mohon MAN, Golassa L, Yewhalaw D, Pillai DR. Asymptomatic malaria in the clinical and public health context. Expert Rev Anti Infect Ther. 2019;17:997\u20131010. https:\/\/doi.org\/10.1080\/14787210.2019.1693259.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"6768_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-022-02504-z","author":"K Stepniewska","year":"2022","unstructured":"Stepniewska K, Allen EN, Humphreys GS, Poirot E, Craig E, Kennon K, et al. Safety of single-dose primaquine as a Plasmodium falciparum gametocytocide: a systematic review and meta-analysis of individual patient data. BMC Med. 2022;20(1):350. https:\/\/doi.org\/10.1186\/s12916-022-02504-z.","journal-title":"BMC Med"},{"key":"6768_CR12","doi-asserted-by":"publisher","unstructured":"Mwaiswelo RO, Ngasala B, Msolo D, Kweka E, Mmbando BP, M\u00e5rtensson A. A single low dose of primaquine is safe and sufficient to reduce transmission of Plasmodium falciparum gametocytes regardless of cytochrome P450 2D6 enzyme activity in Bagamoyo district, Tanzania. Malar J. 2022;21:84. https:\/\/doi.org\/10.1186\/s12936-022-04100-1.","DOI":"10.1186\/s12936-022-04100-1"},{"key":"6768_CR13","doi-asserted-by":"publisher","unstructured":"Habtamu K, Getachew H, Abossie A, Demissew A, Tsegaye A, Degefa T, et al. The effect of single low-dose primaquine treatment for uncomplicated Plasmodium falciparum malaria on haemoglobin levels in Ethiopia: a longitudinal cohort study. Malar J. 2024;23:208. https:\/\/doi.org\/10.1186\/s12936-024-05021-x.","DOI":"10.1186\/s12936-024-05021-x"},{"key":"6768_CR14","doi-asserted-by":"publisher","DOI":"10.1101\/2024.07.17.24310593","author":"E-h Ba KonkoCir\u00e9","year":"2024","unstructured":"Ba KonkoCir\u00e9 E-h, Roh ME, Diallo A, Gadiaga T, Seck A, Thiam S, et al. Mass drug administration to reduce malaria incidence in a low-to-moderate endemic setting: short-term impact results from a cluster randomised controlled trial in Senegal. medRxiv. 2024. https:\/\/doi.org\/10.1101\/2024.07.17.24310593.","journal-title":"medRxiv"},{"key":"6768_CR15","doi-asserted-by":"publisher","unstructured":"Li M, Tuo F, Tan R, Zhang H, Zheng S, Wang Q, et al. Mass drug administration with artemisinin-piperaquine for the elimination of residual foci of malaria in S\u00e3o Tom\u00e9 Island. Front Med. 2021;:8:617195. https:\/\/doi.org\/10.3389\/fmed.2021.617195.","DOI":"10.3389\/fmed.2021.617195"},{"key":"6768_CR16","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1093\/infdis\/jiaa434","volume":"225","author":"M Fraser","year":"2022","unstructured":"Fraser M, Miller JM, Silumbe K, Hainsworth M, Mudenda M, Hamainza B, et al. Evaluating the impact of programmatic mass drug administration for malaria in zambia using routine incidence data. J Infect Dis. 2022;225:1415\u201323. https:\/\/doi.org\/10.1093\/infdis\/jiaa434.","journal-title":"J Infect Dis"},{"key":"6768_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.pmedr.2023.102154","author":"G Li","year":"2023","unstructured":"Li G, Zheng S, Zhang Z, Hu Y, Lin N, Julie N, et al. A campaign of mass drug administration with artemisinin-piperaquine to antimalaria in Trobriand Islands. Prevent Med Rep. 2023;32:102154. https:\/\/doi.org\/10.1016\/j.pmedr.2023.102154.","journal-title":"Prevent Med Rep"},{"key":"6768_CR18","doi-asserted-by":"publisher","first-page":"ofad076","DOI":"10.1093\/ofid\/ofad076","volume":"10","author":"C Deng","year":"2023","unstructured":"Deng C, Wu W, Yuan Y, Li G, Zhang H, Zheng S, et al. Malaria control by mass drug administration with artemisinin plus piperaquine on grande comore island, union of comoros. Open Forum Infect Dis. 2023;10:ofad076. https:\/\/doi.org\/10.1093\/ofid\/ofad076.","journal-title":"Open Forum Infect Dis"},{"key":"6768_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2022.106658","author":"G Li","year":"2022","unstructured":"Li G, Yuan Y, Zheng S, Lu C, Li M, Tan R, et al. Artemisinin-piperaquine versus artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Grande Comore island: an open-label, non-randomised controlled trial. Int J Antimicrob Agents. 2022;60(4):106658. https:\/\/doi.org\/10.1016\/j.ijantimicag.2022.106658.","journal-title":"Int J Antimicrob Agents"},{"key":"6768_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-9-57","author":"DS Jianping Song","year":"2010","unstructured":"Jianping Song DS, Tan B, Dara P, Deng C, Sokunthea S, Seila S, et al. Rapid and effective malaria control in Cambodia through mass administration of artemisinin-piperaquine. Malar J. 2010;9:57. https:\/\/doi.org\/10.1186\/1475-2875-9-57.","journal-title":"Malar J"},{"key":"6768_CR21","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1093\/infdis\/jiw416","volume":"214","author":"TP Eisele","year":"2016","unstructured":"Eisele TP, Bennett A, Silumbe K, Finn TP, Chalwe V, Kamuliwo M, et al. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in southern province Zambia: a cluster-randomized controlled trial. J Infect Dis. 2016;214:1831\u20139. https:\/\/doi.org\/10.1093\/infdis\/jiw416.","journal-title":"J Infect Dis"},{"key":"6768_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0208912","author":"AJF Luty","year":"2018","unstructured":"Luty AJF, Adhikari B, Phommasone K, Pongvongsa T, Soundala X, Koummarasy P, et al. Perceptions of asymptomatic malaria infection and their implications for malaria control and elimination in Laos. Plos ONE. 2018;13(12):e0208912. https:\/\/doi.org\/10.1371\/journal.pone.0208912.","journal-title":"Plos ONE"},{"key":"6768_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-023-04469-7","author":"L Grout","year":"2023","unstructured":"Grout L, KatualaGivo Y, Newport T, Mahamat TA, Gitahi P, Mandagot JJ, et al. Effect of large-scale mass drug administration for malaria on mortality and morbidity in Angumu health zone, Ituri, Democratic Republic of Congo. Malar J. 2023. https:\/\/doi.org\/10.1186\/s12936-023-04469-7.","journal-title":"Malar J"},{"key":"6768_CR24","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1473-3099(20)30997-X","volume":"21","author":"ARD McLean","year":"2021","unstructured":"McLean ARD, Indrasuta C, Khant ZS, Phyo AK, Maung SM, Heaton J, et al. Mass drug administration for the acceleration of malaria elimination in a region of Myanmar with artemisinin-resistant falciparum malaria: a cluster-randomised trial. Lancet Infect Dis. 2021;21:1579\u201389. https:\/\/doi.org\/10.1016\/S1473-3099(20)30997-X.","journal-title":"Lancet Infect Dis"},{"key":"6768_CR25","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy364","author":"C Deng","year":"2018","unstructured":"Deng C, Huang B, Wang Q, Wu W, Zheng S, Zhang H, et al. Large-scale artemisinin-piperaquine mass drug administration with or without primaquine dramatically reduces malaria in a highly endemic region of Africa. Clin Infect Dis. 2018;67(11):1670-6. https:\/\/doi.org\/10.1093\/cid\/ciy364.","journal-title":"Clin Infect Dis"},{"key":"6768_CR26","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.51773","author":"B Gao","year":"2020","unstructured":"Gao B, Saralamba S, Lubell Y, White LJ, Dondorp AM, Aguas R. Determinants of MDA impact and designing MDAs towards malaria elimination. eLife. 2020;9:e51773. https:\/\/doi.org\/10.7554\/eLife.51773.","journal-title":"eLife"},{"key":"6768_CR27","doi-asserted-by":"publisher","DOI":"10.2196\/preprints.51993","author":"J Kaewkungwal","year":"2024","unstructured":"Kaewkungwal J, Roobsoong W, Lawpoolsri S, Nguitragool W, Thammapalo S, Prikchoo P, et al. Effectiveness, safety, and acceptability of primaquine mass drug administration in low-endemicity areas in Southern Thailand: proof-of-concept study. JMIR Public Health Surveill. 2024;10:e51993. https:\/\/doi.org\/10.2196\/preprints.51993.","journal-title":"JMIR Public Health Surveill"},{"key":"6768_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0283160","author":"JLF Vieira","year":"2023","unstructured":"Vieira JLF, Cuinhane CE, Galatas B, Lopez JM, Djive H, Nhantumbo H, et al. Acceptability and perceived barriers to reactive focal mass drug administration in the context of a malaria elimination program in Magude district, Southern Mozambique: a qualitative study. Plos ONE. 2023;18(3):e0283160. https:\/\/doi.org\/10.1371\/journal.pone.0283160.","journal-title":"Plos ONE"},{"key":"6768_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-022-14200-x","author":"Z Zerdo","year":"2022","unstructured":"Zerdo Z, Anthierens S, Van Geertruyden J-P, Massebo F, Biresaw G, Shewangizaw M, et al. Implementation of a malaria prevention education intervention in Southern Ethiopia: a qualitative evaluation. BMC Public Health. 2022;22(1):1811. https:\/\/doi.org\/10.1186\/s12889-022-14200-x.","journal-title":"BMC Public Health"},{"key":"6768_CR30","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1093\/cid\/ciy870","volume":"69","author":"J Mwesigwa","year":"2019","unstructured":"Mwesigwa J, Achan J, Affara M, Wathuo M, Worwui A, Mohammed NI, et al. Mass drug administration with dihydroartemisinin-piperaquine and malaria transmission dynamics in the Gambia: a prospective cohort study. Clin Infect Dis. 2019;69:278\u201386. https:\/\/doi.org\/10.1093\/cid\/ciy870.","journal-title":"Clin Infect Dis"},{"key":"6768_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-55437-8","author":"W Kagaya","year":"2019","unstructured":"Kagaya W, Gitaka J, Chan CW, Kongere J, Md Idris Z, Deng C, et al. Malaria resurgence after significant reduction by mass drug administration on Ngodhe Island, Kenya. Sci Rep. 2019;9(1):19060. https:\/\/doi.org\/10.1038\/s41598-019-55437-8.","journal-title":"Sci Rep"},{"key":"6768_CR32","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1093\/infdis\/jiy686","volume":"219","author":"V Chaumeau","year":"2019","unstructured":"Chaumeau V, Kajeechiwa L, Fustec B, Landier J, NawNyo S, Nay Hsel S, et al. Contribution of asymptomatic Plasmodium infections to the transmission of malaria in Kayin State, Myanmar. J Infect Dis. 2019;219:1499\u2013509. https:\/\/doi.org\/10.1093\/infdis\/jiy686.","journal-title":"J Infect Dis"},{"key":"6768_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.1058660","author":"B Abuaku","year":"2023","unstructured":"Abuaku B, Boateng P, Peprah NY, Asamoah A, Duah-Quashie NO, Matrevi SA, et al. Therapeutic efficacy of dihydroartemisinin-piperaquine combination for the treatment of uncomplicated malaria in Ghana. Front Cell Infect Microbiol. 2023;12:1058660. https:\/\/doi.org\/10.3389\/fcimb.2022.1058660.","journal-title":"Front Cell Infect Microbiol"},{"key":"6768_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002745","author":"JG Beeson","year":"2019","unstructured":"Beeson JG, von Seidlein L, Peto TJ, Landier J, Nguyen T-N, Tripura R, et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in Southeast Asia: a cluster randomised trial. PLOS Med. 2019;16(2):e1002745. https:\/\/doi.org\/10.1371\/journal.pmed.1002745.","journal-title":"PLOS Med"},{"key":"6768_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-023-04543-0","author":"A Vigodny","year":"2023","unstructured":"Vigodny A, Ben Aharon M, Wharton-Smith A, Fialkoff Y, Houri-Yafin A, Bragan\u00e7a F, et al. Digitally managed larviciding as a cost-effective intervention for urban malaria: operational lessons from a pilot in S\u00e3o Tom\u00e9 and Pr\u00edncipe guided by the Zzapp system. Malar J. 2023;22(1):114. https:\/\/doi.org\/10.1186\/s12936-023-04543-0.","journal-title":"Malar J"}],"container-title":["Parasites &amp; Vectors"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13071-025-06768-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13071-025-06768-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13071-025-06768-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T13:58:52Z","timestamp":1747403932000},"score":1,"resource":{"primary":{"URL":"https:\/\/parasitesandvectors.biomedcentral.com\/articles\/10.1186\/s13071-025-06768-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,16]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6768"],"URL":"https:\/\/doi.org\/10.1186\/s13071-025-06768-1","relation":{},"ISSN":["1756-3305"],"issn-type":[{"value":"1756-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,16]]},"assertion":[{"value":"16 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The studies involving human participants were reviewed and approved by the Ethics Committee of the Centro Nacional de Endemias of S\u00e3o Tom\u00e9 and Principe (Approval number: 38\/GMS\/2022) and the Ethics Committee of the Guangdong Provincial Hospital of Chinese Medicine (Approval number: BF2019-055\u201301). Written informed consent to participate in this study was provided by the participants and or their legal guardian\/next of kin.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This study is published with the permission of all authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"177"}}